US5326570A
(en)
*
|
1991-07-23 |
1994-07-05 |
Pharmavene, Inc. |
Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
|
FR2702148B1
(fr)
*
|
1993-03-05 |
1995-04-07 |
Rhone Poulenc Rorer Sa |
Application d'anticonvulsivants dans le traitement du neuro-sida.
|
US6440457B1
(en)
*
|
1993-05-27 |
2002-08-27 |
Alza Corporation |
Method of administering antidepressant dosage form
|
WO1995003052A1
(en)
*
|
1993-07-22 |
1995-02-02 |
Warner-Lambert Company |
Controlled release tacrine drug delivery systems and methods for preparing same
|
US5472714A
(en)
*
|
1993-09-08 |
1995-12-05 |
Ciba-Geigy Corporation |
Double-layered oxcarbazepine tablets
|
ES2270426T3
(es)
*
|
1994-03-18 |
2007-04-01 |
Supernus Pharmaceuticals, Inc. |
Sistema de suministros de farmacos emulsionados.
|
US5536507A
(en)
*
|
1994-06-24 |
1996-07-16 |
Bristol-Myers Squibb Company |
Colonic drug delivery system
|
US5534263A
(en)
|
1995-02-24 |
1996-07-09 |
Alza Corporation |
Active agent dosage form comprising a matrix and at least two insoluble bands
|
US5698210A
(en)
|
1995-03-17 |
1997-12-16 |
Lee County Mosquito Control District |
Controlled delivery compositions and processes for treating organisms in a column of water or on land
|
TW487582B
(en)
*
|
1995-08-11 |
2002-05-21 |
Nissan Chemical Ind Ltd |
Method for converting sparingly water-soluble medical substance to amorphous state
|
US5837284A
(en)
*
|
1995-12-04 |
1998-11-17 |
Mehta; Atul M. |
Delivery of multiple doses of medications
|
US6486177B2
(en)
*
|
1995-12-04 |
2002-11-26 |
Celgene Corporation |
Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
|
US5922736A
(en)
*
|
1995-12-04 |
1999-07-13 |
Celegene Corporation |
Chronic, bolus administration of D-threo methylphenidate
|
US6572880B2
(en)
|
1996-10-24 |
2003-06-03 |
Pharmaceutical Applications Associates Llc |
Methods and transdermal compositions for pain relief
|
US6479074B2
(en)
|
1996-10-24 |
2002-11-12 |
Pharmaceutical Applications Associates Llc |
Methods and transdermal compositions for pain relief
|
US6290986B1
(en)
|
1996-10-24 |
2001-09-18 |
Pharmaceutical Applications Associates, Llc |
Method and composition for transdermal administration of pharmacologic agents
|
US6919373B1
(en)
|
1996-11-12 |
2005-07-19 |
Alza Corporation |
Methods and devices for providing prolonged drug therapy
|
EP0951278A2
(en)
*
|
1997-01-03 |
1999-10-27 |
ELAN CORPORATION, Plc |
Sustained release cisapride mini-tablet formulation
|
US5848966A
(en)
*
|
1997-03-04 |
1998-12-15 |
Graphic Controls Corporation |
Medical device easily removed from skin and a method of removal therefrom
|
CA2216215A1
(en)
*
|
1997-04-05 |
1998-10-05 |
Isa Odidi |
Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
|
US6962997B1
(en)
*
|
1997-05-22 |
2005-11-08 |
Celgene Corporation |
Process and intermediates for resolving piperidyl acetamide steroisomers
|
DE19724696A1
(de)
*
|
1997-06-12 |
1998-12-24 |
Hexal Ag |
Pharmazeutische Zubereitung mit drei Pelletarten
|
AU5155198A
(en)
*
|
1997-08-28 |
1999-03-22 |
Robert Murdock |
Method and composition for transdermal administration of pharmacologic agent
|
FR2771292B1
(fr)
*
|
1997-11-21 |
2000-02-18 |
Ethypharm Lab Prod Ethiques |
Spheroides contenant de la tiagabine, procede de preparation et compositions pharmaceutiques
|
DE19809719A1
(de)
*
|
1998-03-06 |
1999-09-09 |
Roehm Gmbh |
Wäßrige Dispersion geeignet zur Herstellung von Überzugs- und Bindemitteln für feste orale Arzneiformen
|
US6211194B1
(en)
*
|
1998-04-30 |
2001-04-03 |
Duke University |
Solution containing nicotine
|
US6365183B1
(en)
|
1998-05-07 |
2002-04-02 |
Alza Corporation |
Method of fabricating a banded prolonged release active agent dosage form
|
UA69413C2
(uk)
*
|
1998-05-22 |
2004-09-15 |
Брістол-Майерс Сквібб Компані |
Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
|
US7122207B2
(en)
*
|
1998-05-22 |
2006-10-17 |
Bristol-Myers Squibb Company |
High drug load acid labile pharmaceutical composition
|
UA73092C2
(uk)
|
1998-07-17 |
2005-06-15 |
Брістол-Майерс Сквібб Компані |
Таблетка з ентеросолюбільним покриттям і спосіб її приготування
|
US6706282B1
(en)
*
|
1998-11-02 |
2004-03-16 |
Evangeline Cruz |
Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
|
US6673367B1
(en)
|
1998-12-17 |
2004-01-06 |
Euro-Celtique, S.A. |
Controlled/modified release oral methylphenidate formulations
|
US6419960B1
(en)
|
1998-12-17 |
2002-07-16 |
Euro-Celtique S.A. |
Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
|
US7083808B2
(en)
*
|
1998-12-17 |
2006-08-01 |
Euro-Celtique S.A. |
Controlled/modified release oral methylphenidate formulations
|
US6162466A
(en)
*
|
1999-04-15 |
2000-12-19 |
Taro Pharmaceutical Industries Ltd. |
Sustained release formulation of carbamazepine
|
EP1206250A2
(en)
*
|
1999-08-26 |
2002-05-22 |
ELAN CORPORATION, Plc |
Pharmaceutical formulations with different release times
|
CA2399856C
(en)
*
|
2000-02-24 |
2009-01-27 |
Edward M. Rudnic |
Antibiotic composition with inhibitor
|
AU2001239838A1
(en)
*
|
2000-02-24 |
2001-09-03 |
Advancis Pharmaceutical Corporation |
Therapeutic product, use and formulation thereof
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
US6991807B2
(en)
*
|
2000-02-24 |
2006-01-31 |
Advancis Pharmaceutical, Corp. |
Antibiotic composition
|
US7025989B2
(en)
*
|
2000-02-24 |
2006-04-11 |
Advancis Pharmaceutical Corp. |
Multiple-delayed released antibiotic product, use and formulation thereof
|
US6623757B2
(en)
*
|
2000-02-24 |
2003-09-23 |
Advancis Pharmaceutical Corp. |
Antibiotic composition
|
AR030557A1
(es)
*
|
2000-04-14 |
2003-08-27 |
Jagotec Ag |
Una tableta en multicapa de liberacion controlada y metodo de tratamiento
|
US20040122090A1
(en)
*
|
2001-12-07 |
2004-06-24 |
Lipton Stuart A. |
Methods for treating neuropsychiatric disorders with nmda receptor antagonists
|
US6524617B1
(en)
*
|
2001-07-25 |
2003-02-25 |
Isp Investments Inc. |
Synergistic filler composition
|
US20030228368A1
(en)
*
|
2001-09-28 |
2003-12-11 |
David Wynn |
Edible solid composition and dosage form
|
US20040213848A1
(en)
*
|
2001-09-28 |
2004-10-28 |
Shun-Por Li |
Modified release dosage forms
|
US20040146559A1
(en)
*
|
2002-09-28 |
2004-07-29 |
Sowden Harry S. |
Dosage forms having an inner core and outer shell with different shapes
|
US7838026B2
(en)
|
2001-09-28 |
2010-11-23 |
Mcneil-Ppc, Inc. |
Burst-release polymer composition and dosage forms comprising the same
|
US7122143B2
(en)
|
2001-09-28 |
2006-10-17 |
Mcneil-Ppc, Inc. |
Methods for manufacturing dosage forms
|
US20040253312A1
(en)
*
|
2001-09-28 |
2004-12-16 |
Sowden Harry S. |
Immediate release dosage form comprising shell having openings therein
|
US6837696B2
(en)
*
|
2001-09-28 |
2005-01-04 |
Mcneil-Ppc, Inc. |
Apparatus for manufacturing dosage forms
|
US6635675B2
(en)
|
2001-11-05 |
2003-10-21 |
Cypress Bioscience, Inc. |
Method of treating chronic fatigue syndrome
|
US6602911B2
(en)
|
2001-11-05 |
2003-08-05 |
Cypress Bioscience, Inc. |
Methods of treating fibromyalgia
|
CA2478121A1
(en)
*
|
2002-03-07 |
2003-09-18 |
Advancis Pharmaceutical Corporation |
Antibiotic composition
|
US6572889B1
(en)
*
|
2002-03-07 |
2003-06-03 |
Noveon Ip Holdings Corp. |
Controlled release solid dosage carbamazepine formulations
|
CA2483827C
(en)
*
|
2002-04-29 |
2012-01-24 |
Amir H. Shojaei |
Pharmaceutical formulations with improved bioavailability
|
MXPA04011801A
(es)
*
|
2002-05-31 |
2005-09-12 |
Desitin Arzneimittel Gmbh |
Composicion farmaceutica que contiene oxcarbazepina con liberacion controlada de la substancia activa.
|
US7939102B2
(en)
*
|
2002-06-07 |
2011-05-10 |
Torrent Pharmaceuticals Ltd. |
Controlled release formulation of lamotrigine
|
US20040006072A1
(en)
*
|
2002-06-25 |
2004-01-08 |
Franz Robert M. |
Sustained-release alprazolam composition
|
AU2003265446A1
(en)
*
|
2002-08-13 |
2004-02-25 |
Medtronic, Inc. |
Active agent delivery system including a hydrophilic polymer, medical device, and method
|
JP2006500088A
(ja)
*
|
2002-08-13 |
2006-01-05 |
メドトロニック・インコーポレーテッド |
ポリマーの被覆及び支持体間の改良された付着を示す医用デバイス
|
EP1536846A1
(en)
*
|
2002-08-13 |
2005-06-08 |
Medtronic, Inc. |
Active agent delivery system including a polyurethane, medical device, and method
|
CA2495172A1
(en)
*
|
2002-08-13 |
2004-02-19 |
Medtronic, Inc. |
Active agent delivery systems, medical devices, and methods
|
DE60316579T2
(de)
*
|
2002-08-13 |
2008-07-03 |
Medtronic, Inc., Minneapolis |
System zur abgabe von wirkstoffen mit einem hydrophoben cellulose-derivat
|
US7807197B2
(en)
*
|
2002-09-28 |
2010-10-05 |
Mcneil-Ppc, Inc. |
Composite dosage forms having an inlaid portion
|
MY148805A
(en)
*
|
2002-10-16 |
2013-05-31 |
Takeda Pharmaceutical |
Controlled release preparation
|
KR20050096922A
(ko)
|
2002-12-20 |
2005-10-06 |
니코노범 에이비 |
물리적 및 화학적으로 안정된 니코틴 함유 입자물질
|
JP3811127B2
(ja)
*
|
2003-01-30 |
2006-08-16 |
株式会社東芝 |
情報記録装置及び情報記録方法
|
WO2005009364A2
(en)
*
|
2003-07-21 |
2005-02-03 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
WO2005009365A2
(en)
*
|
2003-07-21 |
2005-02-03 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
WO2005009368A2
(en)
*
|
2003-07-21 |
2005-02-03 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
AU2004264356B2
(en)
*
|
2003-08-12 |
2011-01-27 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
EP1684820A2
(en)
*
|
2003-08-13 |
2006-08-02 |
Medtronic, Inc. |
Active agent delivery systems including a miscible polymer blend, medical devices, and methods
|
WO2005023184A2
(en)
|
2003-08-29 |
2005-03-17 |
Advancis Pharmaceuticals Corporation |
Antibiotic product, use and formulation thereof
|
CA2538929A1
(en)
*
|
2003-09-11 |
2005-03-24 |
Glykon Technologies Group, Llc |
Enteric delivery of (-)-hydroxycitric acid
|
WO2005027877A1
(en)
*
|
2003-09-15 |
2005-03-31 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
US20050069590A1
(en)
*
|
2003-09-30 |
2005-03-31 |
Buehler Gail K. |
Stable suspensions for medicinal dosages
|
US20050074514A1
(en)
*
|
2003-10-02 |
2005-04-07 |
Anderson Oliver B. |
Zero cycle molding systems, methods and apparatuses for manufacturing dosage forms
|
EP1679066A4
(en)
*
|
2003-10-27 |
2011-06-22 |
Astellas Pharma Inc |
MEDICINAL COATING MICROPARTICLES FOR A MOUTH-DISABLE TABLET
|
PT2210605T
(pt)
*
|
2003-11-04 |
2017-04-24 |
Tcd Royalty Sub Llc |
Formas de dosagem única diária de tróspio
|
WO2005046663A1
(en)
|
2003-11-04 |
2005-05-26 |
Shire Laboratories, Inc. |
Compositions of quaternary ammonium containing bioavailability enhancers
|
EP1691789B1
(en)
|
2003-11-25 |
2017-12-20 |
SmithKline Beecham (Cork) Limited |
Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
|
CA2452588C
(en)
*
|
2003-12-08 |
2015-05-19 |
Shire Pharmaceutical Development Inc. |
Methods for the treatment of bipolar disorder using carbamazepine
|
US20060094709A1
(en)
*
|
2003-12-08 |
2006-05-04 |
Kalali Amir H |
Methods for the treatment of bipolar disorder using carbamazepine
|
US20050142203A1
(en)
*
|
2003-12-30 |
2005-06-30 |
Grant Heinicke |
Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
|
US8067029B2
(en)
*
|
2004-01-13 |
2011-11-29 |
Mcneil-Ppc, Inc. |
Rapidly disintegrating gelatinous coated tablets
|
US7879354B2
(en)
|
2004-01-13 |
2011-02-01 |
Mcneil-Ppc, Inc. |
Rapidly disintegrating gelatinous coated tablets
|
CA2554959A1
(en)
*
|
2004-01-29 |
2005-08-11 |
Neuromolecular, Inc. |
Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
|
US20050196442A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Huang Hai Y. |
Polymeric compositions and dosage forms comprising the same
|
US20050196446A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Huang Hai Y. |
Polymeric compositions and dosage forms comprising the same
|
US20050196448A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Hai Yong Huang |
Polymeric compositions and dosage forms comprising the same
|
US20050196447A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Huang Hai Y. |
Polymeric compositions and dosage forms comprising the same
|
US20050239830A1
(en)
*
|
2004-04-26 |
2005-10-27 |
Vikram Khetani |
Methods of diminishing co-abuse potential
|
US20060087051A1
(en)
*
|
2004-10-27 |
2006-04-27 |
Bunick Frank J |
Dosage forms having a microreliefed surface and methods and apparatus for their production
|
US20060088593A1
(en)
*
|
2004-10-27 |
2006-04-27 |
Bunick Frank J |
Dosage forms having a microreliefed surface and methods and apparatus for their production
|
US20060088586A1
(en)
*
|
2004-10-27 |
2006-04-27 |
Bunick Frank J |
Dosage forms having a microreliefed surface and methods and apparatus for their production
|
US8383159B2
(en)
*
|
2004-10-27 |
2013-02-26 |
Mcneil-Ppc, Inc. |
Dosage forms having a microreliefed surface and methods and apparatus for their production
|
US20060088587A1
(en)
*
|
2004-10-27 |
2006-04-27 |
Bunick Frank J |
Dosage forms having a microreliefed surface and methods and apparatus for their production
|
US20070281022A1
(en)
*
|
2004-10-27 |
2007-12-06 |
Bunick Frank J |
Dosage forms having a microreliefed surface and methods and apparatus for their production
|
US20070190133A1
(en)
*
|
2004-10-27 |
2007-08-16 |
Bunick Frank J |
Dosage forms having a microreliefed surface and methods and apparatus for their production
|
SG157415A1
(en)
|
2004-11-23 |
2009-12-29 |
Adamas Pharmaceuticals Inc |
Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
|
US7619007B2
(en)
|
2004-11-23 |
2009-11-17 |
Adamas Pharmaceuticals, Inc. |
Method and composition for administering an NMDA receptor antagonist to a subject
|
CA2588296A1
(en)
|
2004-11-24 |
2006-06-01 |
Neuromolecular Pharmaceuticals, Inc. |
Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
|
CA2591247A1
(en)
*
|
2004-12-09 |
2006-06-15 |
Celgene Corporation |
Treatment of patients suffering from a disease having a family history or diagnosis of tics or tourette's syndrome with d-threo methylphenidate
|
US20060182805A1
(en)
*
|
2005-02-15 |
2006-08-17 |
Jazz Pharmaceuticals |
Dosage form and method for sustained release of substituted pyrazine compound
|
US20090169619A1
(en)
*
|
2005-02-25 |
2009-07-02 |
Corepharma Llc |
Carbamazepine extended release dosage form
|
WO2006121560A2
(en)
|
2005-04-06 |
2006-11-16 |
Adamas Pharmaceuticals, Inc. |
Methods and compositions for treatment of cns disorders
|
US8673352B2
(en)
|
2005-04-15 |
2014-03-18 |
Mcneil-Ppc, Inc. |
Modified release dosage form
|
WO2006116247A1
(en)
*
|
2005-04-25 |
2006-11-02 |
Teva Pharmaceuticals Usa, Inc. |
Extended release formulations
|
US20060252745A1
(en)
|
2005-05-06 |
2006-11-09 |
Almeida Jose L D |
Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
|
US20070071819A1
(en)
*
|
2005-05-30 |
2007-03-29 |
Kesarwani Amit K |
Multiple unit modified release compositions of carbamazepine and process for their preparation
|
US7994220B2
(en)
*
|
2005-09-28 |
2011-08-09 |
Cypress Bioscience, Inc. |
Milnacipran for the long-term treatment of fibromyalgia syndrome
|
US20070077300A1
(en)
|
2005-09-30 |
2007-04-05 |
Wynn David W |
Oral compositions containing a salivation inducing agent
|
US8440695B2
(en)
*
|
2005-11-09 |
2013-05-14 |
St Jude Children's Research Hospital |
Use of chloroquine to treat metabolic syndrome
|
AU2007224584A1
(en)
|
2006-03-16 |
2007-09-20 |
Niconovum Ab |
Improved snuff composition
|
CN101453996B
(zh)
*
|
2006-04-03 |
2016-05-11 |
伊萨·奥迪迪 |
药物递送组合物
|
EP2018157A2
(en)
*
|
2006-04-26 |
2009-01-28 |
Astron Research Limited |
Controlled release formulation comprising anti-epileptic drugs
|
DE602007012236D1
(de)
*
|
2006-04-26 |
2011-03-10 |
Supernus Pharmaceuticals Inc |
Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil
|
AU2013200237B2
(en)
*
|
2006-04-26 |
2015-07-16 |
Supernus Pharmaceuticals, Inc. |
Controlled released preparations of oxcarbazepine having sigmoidal release profile
|
US8124598B2
(en)
*
|
2006-09-14 |
2012-02-28 |
Sharon Sageman |
7-keto DHEA for psychiatric use
|
BRPI0716995A2
(pt)
*
|
2006-09-27 |
2013-10-15 |
Niconovum Ab |
Métodos para administração oral de um líquido, e para aplicação de gotículas líquidas ou líquido atomizado contendo uma substância ativa no interior da boca de um indivíduo, dispositivo de pulverização, uso de um líquido, kit, e, uso de um kit
|
US8580855B2
(en)
|
2006-10-20 |
2013-11-12 |
Mcneil-Ppc, Inc. |
Acetaminophen / ibuprofen combinations and method for their use
|
US7731604B2
(en)
*
|
2006-10-31 |
2010-06-08 |
Taylor Made Golf Company, Inc. |
Golf club iron head
|
AU2007319141B2
(en)
|
2006-11-17 |
2013-01-10 |
Supernus Pharmaceuticals Inc. |
Sustained-release formulations of topiramate
|
US20080317678A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Szymczak Christopher E |
Laser Marked Dosage Forms
|
US20080317677A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Szymczak Christopher E |
Laser Marked Dosage Forms
|
US20090060983A1
(en)
*
|
2007-08-30 |
2009-03-05 |
Bunick Frank J |
Method And Composition For Making An Orally Disintegrating Dosage Form
|
US20100160274A1
(en)
*
|
2007-09-07 |
2010-06-24 |
Sharon Sageman |
7-KETO DHEA for Psychiatric Use
|
EP2203056A1
(en)
*
|
2007-09-25 |
2010-07-07 |
Nirmal Mulye |
Controlled release pharmaceutical compositions
|
US8372431B2
(en)
*
|
2007-10-26 |
2013-02-12 |
Bial-Portela & C.A., S.A. |
Pharmaceutical composition comprising licarbazepine acetate
|
CN101842085B
(zh)
*
|
2007-10-31 |
2013-01-30 |
麦克内尔-Ppc股份有限公司 |
口腔崩解剂型
|
US20090143362A1
(en)
*
|
2007-12-04 |
2009-06-04 |
Barabde Umesh Vinayakrao |
Carbamazepine formulations
|
US8357395B2
(en)
*
|
2007-12-21 |
2013-01-22 |
Mcneil-Ppc, Inc. |
Manufacture of tablet
|
US20100285119A1
(en)
*
|
2008-01-11 |
2010-11-11 |
Jubilant Organosys Ltd. |
Multiparticulate Extended Release Pharmaceutical Composition Of Carbamazepine And Process For Manufacturing The Same
|
BRPI0915411A2
(pt)
*
|
2008-06-26 |
2015-11-03 |
Mcneil Ppc Inc |
partículas revestidas contendo agentes farmaceuticamente ativos
|
EP2331088A4
(en)
|
2008-08-06 |
2011-10-12 |
Gosforth Ct Holdings Pty Ltd |
COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
|
WO2010031552A1
(en)
*
|
2008-09-17 |
2010-03-25 |
Niconovum Ab |
Process for preparing snuff composition
|
US20100233259A1
(en)
*
|
2008-12-12 |
2010-09-16 |
Pascal Grenier |
Dosage form of ropinirole
|
US8313768B2
(en)
|
2009-09-24 |
2012-11-20 |
Mcneil-Ppc, Inc. |
Manufacture of tablet having immediate release region and sustained release region
|
US20110070286A1
(en)
*
|
2009-09-24 |
2011-03-24 |
Andreas Hugerth |
Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process
|
US9610224B2
(en)
*
|
2009-09-24 |
2017-04-04 |
Johnson & Johnson Consumer Inc. |
Manufacture of tablet in a die utilizing powder blend containing water-containing material
|
US20110318411A1
(en)
|
2010-06-24 |
2011-12-29 |
Luber Joseph R |
Multi-layered orally disintegrating tablet and the manufacture thereof
|
BR112012013487A2
(pt)
|
2009-12-02 |
2017-10-03 |
Adamas Pharmaceuticals Inc |
Composições de amantadina e métodos de uso
|
GB201111712D0
(en)
|
2011-07-08 |
2011-08-24 |
Gosforth Ct Holdings Pty Ltd |
Pharmaceutical compositions
|
WO2013054178A2
(en)
*
|
2011-10-14 |
2013-04-18 |
Micro Labs Limited |
Extended release pharmaceutical compositions containing carmabazepine
|
US9445971B2
(en)
|
2012-05-01 |
2016-09-20 |
Johnson & Johnson Consumer Inc. |
Method of manufacturing solid dosage form
|
US9233491B2
(en)
|
2012-05-01 |
2016-01-12 |
Johnson & Johnson Consumer Inc. |
Machine for production of solid dosage forms
|
US9511028B2
(en)
|
2012-05-01 |
2016-12-06 |
Johnson & Johnson Consumer Inc. |
Orally disintegrating tablet
|
US8999393B1
(en)
|
2013-01-09 |
2015-04-07 |
Edgemont Pharmaceuticals Llc |
Sustained release formulations of lorazepam
|
US10154971B2
(en)
|
2013-06-17 |
2018-12-18 |
Adamas Pharma, Llc |
Methods of administering amantadine
|
US20150133516A1
(en)
|
2013-11-13 |
2015-05-14 |
Brian K. Adams |
Methods and Compositions for Treating ADHD
|
MX368159B
(es)
|
2014-01-10 |
2019-09-20 |
Johnson & Johnson Consumer Inc |
Proceso para elaborar tabletas con el uso de radiofrecuencia y partículas disipativas revestidas.
|
CA2936746C
(en)
|
2014-10-31 |
2017-06-27 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
CN107920995A
(zh)
|
2015-07-02 |
2018-04-17 |
路易斯威尔大学研究基金会 |
用于递送miRNA的源自可食用植物的微囊泡组合物和用于治疗癌症的方法
|
BR112018012870A2
(pt)
|
2015-12-30 |
2018-12-04 |
Adamas Pharmaceuticals Inc |
métodos e composições para o tratamento de transtornos relacionados à crise
|
US10493026B2
(en)
|
2017-03-20 |
2019-12-03 |
Johnson & Johnson Consumer Inc. |
Process for making tablet using radiofrequency and lossy coated particles
|
WO2018200885A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocentria, Inc. |
Magnesium compositions and methods of use
|
JP7273976B2
(ja)
*
|
2018-09-21 |
2023-05-15 |
アムニール コンプレックス プロダクツ リサーチ エルエルシー |
トリヘキシフェニジルを含む徐放性組成物
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|